New CAR t therapy targets two proteins to fight blood cancers
NCT ID NCT07166549
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD20) on B cell cancer cells. It is for adults with B cell leukemia or lymphoma who have run out of standard options, including commercial CAR T cells. The main goal is to check safety, but researchers will also look at how well the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bispecific anti-CD19, anti-CD20 CAR T cells
What this could lead to
If this works, it could offer a new treatment option for people with B cell cancers that have not responded to other therapies, including commercial CAR T cells.
What could go wrong
This is a very early phase 1 trial with only 12 participants, so it is too soon to know if it is safe or effective. There are known risks like cytokine release syndrome and neurological side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University Hospital Basel, Division of Hematology or Medical Oncology
Basel, Canton of Basel-City, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact